Common Contracts
16 similar Underwriting Agreement contracts by MCG Capital Corp, Antigenics Inc /De/, Aphton Corp, others
MCG CAPITAL CORPORATION Shares Common Stock ($.01 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • March 28th, 2008 • MCG Capital Corp • New York
MCG Capital Corporation, a Delaware corporation (the “Company”) proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representative(s), an aggregate of [ ] shares of common stock, $.01 par value per share (the “Common Stock”), of the Company, consisting of [ ] shares (the “Firm Shares” and at the option of the Underwriters solely for the purpose of covering over-allotments, an additional [ ] shares (the “Additional Shares,” and together with the Firm Shares, the “Shares”) of Common Stock to be issued and sold by the Company. The Shares are described in the Prospectus which is referred to below.
MCG CAPITAL CORPORATION Shares Common Stock ($.01 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • April 30th, 2007 • MCG Capital Corp • New York
MCG Capital Corporation, a Delaware corporation (the “Company”) proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representative(s), an aggregate of shares of common stock, $.01 par value per share (the “Common Stock”), of the Company, consisting of shares (the “Firm Shares”) and at the option of the Underwriters solely for the purpose of covering over-allotments, an additional shares (the “Additional Shares,” and together with the Firm Shares, the “Shares”) of Common Stock to be issued and sold by the Company. The Shares are described in the Prospectus which is referred to below.
MCG CAPITAL CORPORATION Shares Common Stock ($.01 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 29th, 2006 • MCG Capital Corp • New York
MCG Capital Corporation, a Delaware corporation (the “Company”) proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representative(s), an aggregate of shares of common stock, $.01 par value per share (the “Common Stock”), of the Company, consisting of shares (the “Firm Shares”) and at the option of the Underwriters solely for the purpose of covering over-allotments, an additional shares (the “Additional Shares,” and together with the Firm Shares, the “Shares”) of Common Stock to be issued and sold by the Company. The Shares are described in the Prospectus which is referred to below.
NEOPHARM, INC. 3,500,000 Shares Common Stock ($0.0002145 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 5th, 2006 • Neopharm Inc • Biological products, (no disgnostic substances) • New York
The Firm has reviewed the Prospectus dated December 17, 2003 and those portions of (a) the January , 2006, Prospectus Supplement to Prospectus dated December 17, 2003, (b) Annual Report on Form 10-K, of NeoPharm, Inc. for the fiscal year ended December 31, 2004, and (c) Form S-3 Registration Statement, entitled “Our inability to adequately protect our proprietary technologies could harm our competitive position and have a material adverse effect on our business,” “We may be sued for infringing on the intellectual property rights of others,” “We depend on intellectual property rights licensed from third parties. If we fail to meet our obligations under license agreements, we may lose our rights to key technologies on which our business depends,” and “We may in the future be a party to patent litigation, which could be expensive and divert our management’s attention,” which are titles being listed under the section titled “Risk Factors.” and a section in the Company’s Form 10-K entitled
GERON CORPORATION 6,000,000 Shares Common Stock ($0.001 par value per Share) Underwriting AgreementUnderwriting Agreement • September 16th, 2005 • Geron Corp • Pharmaceutical preparations • New York
intellectual property which would be necessary for the Company to conduct the business now conducted or proposed to be conducted by the Company as described in the Registration Statements and the Prospectus and for which the Company does not have and will not be able to obtain sufficient rights to conduct such business; and (iii) such counsel is unaware of any facts which provide valid grounds for finding any of the Company’s patents and other intellectual property invalid or unenforceable in all material respects.
4,250,000 Shares Non-Voting Common Stock ($0.10 Par Value) UNDERWRITING AGREEMENT June 9, 2005Underwriting Agreement • June 9th, 2005 • Petroleum Helicopters Inc • Air transportation, nonscheduled • New York
UBS Securities LLC Lehman Brothers Inc. Howard Weil Incorporated Simmons & Company International As Representatives of the several Underwriters
ITRON, INC. 1,500,000 Shares Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 17th, 2005 • Itron Inc /Wa/ • Radio & tv broadcasting & communications equipment • Massachusetts
Itron, Inc., a Washington corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 1,500,000 shares (the “Firm Shares”) of common stock, without par value (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 225,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
5,000,000 Shares JLG INDUSTRIES, INC. Common Stock ($0.20 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • March 16th, 2005 • JLG Industries Inc • Construction machinery & equip • New York
JLG Industries, Inc., a Pennsylvania corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 5,000,000 shares (the “Firm Shares”) of Common Stock, $0.20 par value (the “Common Stock”). In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 750,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” References herein to Common Stock include the related common stock purchase rights under the Rights Agreement, dated as of May 24, 2000, between the Company and American Stock Transfer and Trust Company. The Shares are described in the Prospectus which is referred to below.
ICAGEN, INC. 5,000,000 Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2005 • Icagen Inc • Pharmaceutical preparations • New York
Directors and Officers,” insofar as such information constitutes a summary of the terms of documents or matters of law or legal conclusions, at the time such Registration Statement became effective, as of the date of the Prospectus and at the time of purchase, is complete and accurate in all material respects.
OMEGA HEALTHCARE INVESTORS, INC. 3,500,000 Shares Common Stock ($0.10 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • December 13th, 2004 • Omega Healthcare Investors Inc • Real estate investment trusts • New York
Omega Healthcare Investors, Inc., a real estate investment trust organized under the laws of the State of Maryland (the "Company"), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the "Underwriters") an aggregate of 3,500,000 shares (the "Firm Shares") of common stock, $0.10 par value per share (the "Common Stock"), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 525,000 shares of Common Stock (the "Additional Shares"). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the "Shares." The Shares are described in the Prospectus which is referred to below.
UNDERWRITING AGREEMENTUnderwriting Agreement • August 6th, 2004 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a Washington corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 9,000,000 shares (the “Firm Shares”) of Common Stock, no par value (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,350,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
APHTON CORPORATION 7,000,000 Shares Common Stock ($0.001 par value per Share) Underwriting AgreementUnderwriting Agreement • March 1st, 2004 • Aphton Corp • Biological products, (no disgnostic substances) • New York
Aphton Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 7,000,000 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,050,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
Antigenics Inc. 5,000,000 Shares Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • February 4th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
DENDREON CORPORATION 10,250,000 Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2004 • Dendreon Corp • Pharmaceutical preparations • New York
6,900,000 Shares Common Stock ($0.001 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • August 27th, 2003 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations • New York
SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representative(s), an aggregate of 6,000,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 900,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
ILEX Oncology, Inc. 6,000,000 Shares Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • August 4th, 2003 • Ilex Oncology Inc • Biological products, (no disgnostic substances) • New York
ILEX Oncology, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the Underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representative(s), an aggregate of 5,500,000 shares of Common Stock, $0.01 par value per share (the “Common Stock”), of the Company, and the Cancer Therapy and Research Center Endowment, a non-profit Texas corporation (the “Selling Stockholder”), proposes to sell to the several Underwriters 500,000 shares of Common Stock (said shares to be issued and sold by the Company and to be sold by the Selling Stockholder collectively, the “Firm Shares”). In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 825,000 shares of Common Stock, and the Selling Stockholder proposes to grant to the Underwriters the option to purchase up to an additional 75,000 shares of Common Stock (the 900,000
